{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:30:32Z","timestamp":1793503832793,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cmi.2025.08.018","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T06:34:02Z","timestamp":1755930842000},"page":"1797-1806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["How do I manage difficult-to-treat Pseudomonas aeruginosa infections? Key questions for today\u2019s clinicians"],"prefix":"10.1016","volume":"31","author":[{"given":"Juan P.","family":"Horcajada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Isler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Kwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia B.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Milagro","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Pogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Virginia","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.08.018_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.08.018_bib2","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.08.018_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect Off"},{"key":"10.1016\/j.cmi.2025.08.018_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01281-22","article-title":"In vitro activity of cefepime-taniborbactam and comparators against clinical isolates of gram-negative bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) program","volume":"67","author":"Karlowsky","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01432-20","article-title":"In vitro activity of WCK 5222 (cefepime-zidebactam) against worldwide collected gram-negative bacilli not susceptible to carbapenems","volume":"64","author":"Karlowsky","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib9","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/jac\/dky279","article-title":"Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-2017)","volume":"73","author":"Sader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01587-18","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. Census Divisions: Results from the 2017 INFORM program","volume":"62","author":"Sader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106744","article-title":"Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021)","volume":"61","author":"Sader","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.08.018_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2021.115557","article-title":"Antimicrobial susceptibility of gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018-2020)","volume":"102","author":"Sader","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02431-18","article-title":"Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of enterobacteriaceae and Pseudomonas aeruginosa","volume":"63","author":"Yin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib14","doi-asserted-by":"crossref","first-page":"447.e1","DOI":"10.1016\/j.cmi.2021.07.018","article-title":"In vitro activity of the novel siderophore cephalosporin, cefiderocol, in gram-negative pathogens in Europe by site of infection","volume":"28","author":"Candel","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.08.018_bib15","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","article-title":"The ERACE-PA Global Surveillance Program: Ceftolozane\/tazobactam and Ceftazidime\/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa","volume":"40","author":"Gill","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs. polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jgar.2022.01.023","article-title":"Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: A multicentre cohort study","volume":"28","author":"Almangour","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.08.018_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2147\/IDR.S350976","article-title":"Ceftazidime\/avibactam versus polymyxin B in the challenge of carbapenem-resistant Pseudomonas aeruginosa infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2025.08.018_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13613-022-01084-8","article-title":"Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane\/tazobactam versus meropenem: A subset analysis of the phase 3, randomized, controlled ASPECT-NP trial","volume":"13","author":"Martin-Loeches","year":"2023","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.cmi.2025.08.018_bib20","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1056\/NEJMp2407586","article-title":"\u201cTarget Trial Emulation\u201d for observational studies\u2014potential and pitfalls","volume":"391","author":"Hubbard","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.018_bib21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","article-title":"The target trial framework for causal inference from observational data: Why and when is it helpful?","volume":"178","author":"Hern\u00e1n","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2025.08.018_bib22","article-title":"Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): A multicentre, retrospective, observational study","volume":"S1473\u20133099","author":"Shields","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib23","article-title":"Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia","author":"Shah","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa: A multicenter cohort study","volume":"67","author":"Almangour","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.cmi.2025.08.018_bib26","article-title":"Ceftolozane-tazobactam or ceftazidime-avibactam versus best available therapy in the treatment of difficult-to-treat Pseudomonas aeruginosa infections: A retrospective comparative effectiveness analysis of 195 hospitals, 2016-2020","volume":"9","author":"Lawandi","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib27","first-page":"699","article-title":"Clinical outcomes of ceftazidime-avibactam versus ceftolozane-tazobactam in managing pseudomonal infections in patients undergoing renal replacement therapy","volume":"13","author":"El Nekidy","year":"2024","journal-title":"Antibiot Basel Switz"},{"key":"10.1016\/j.cmi.2025.08.018_bib28","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib29","unstructured":"Cefiderocol_MIC_testing_EUCAST_guidance_document_January_2024.pdf; n.d."},{"key":"10.1016\/j.cmi.2025.08.018_bib30","first-page":"2318","article-title":"Issues with cefiderocol testing: Comparing commercial methods to broth microdilution in iron-depleted medium-analyses of the performances, ATU, and trailing effect according to EUCAST initial and revised interpretation criteria","volume":"14","author":"Stracquadanio","year":"2024","journal-title":"Diagn Basel Switz"},{"key":"10.1016\/j.cmi.2025.08.018_bib31","doi-asserted-by":"crossref","first-page":"652.e1","DOI":"10.1016\/j.cmi.2022.12.021","article-title":"Performance of discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol","volume":"29","author":"Devoos","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.08.018_bib32","article-title":"In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel \u03b2-lactam\/\u03b2-lactamase inhibitors","volume":"5","author":"Shields","year":"2023","journal-title":"JAC-Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.08.018_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01697-22","article-title":"Antimicrobial activity of ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol against multidrug-resistant Pseudomonas aeruginosa recovered at a german university hospital","volume":"10","author":"Weber","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.08.018_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04266-23","article-title":"Resistance to ceftazidime-avibactam and other new \u03b2-lactams in Pseudomonas aeruginosa clinical isolates: A multi-center surveillance study","volume":"12","author":"Valzano","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.08.018_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2025.03.013","article-title":"Emerging resistance mechanisms to newer \u03b2-lactams in Pseudomonas aeruginosa","author":"Oliver","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.08.018_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib37","series-title":"Investigator driven randomized controlled trial of cefiderocol versus standard therapy for healthcare associated and hospital acquired gram-negative bloodstream infection (GAMECHANGER trial)","author":"Paterson","year":"2024"},{"key":"10.1016\/j.cmi.2025.08.018_bib38","unstructured":"Paula R, Esperanza M, Jessica S, Javier Gonzalez A. Real-world effectiveness and safety of cefiderocol in patients with gram-negative bacterial infections in the early access programme in Spain: Results of the PERSEUS study. Barcelona, Spain; n.d."},{"key":"10.1016\/j.cmi.2025.08.018_bib39","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","article-title":"Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: An approach based on the mechanisms of resistance to carbapenems","volume":"48","author":"Karakonstantis","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2025.08.018_bib40","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): A prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2025.08.018_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00785-24","article-title":"\u03b2-Lactamase diversity in Pseudomonas aeruginosa","author":"Mack","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib42","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.ajic.2024.08.022","article-title":"Five-year VIM-producing Pseudomonas aeruginosa outbreak in four Belgian ICUs, an investigation report (2019-2023)","volume":"52","author":"Moretti","year":"2024","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.cmi.2025.08.018_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01220-24","article-title":"Characterization of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa carrying multiple carbapenemase genes\u2014Antimicrobial Resistance Laboratory Network, 2018\u20132022","volume":"62","author":"Sabour","year":"2024","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.08.018_bib44","first-page":"1138","article-title":"Ciprofloxacin for the treatment of infections caused by carbapenemase-producing gram-negative bacteria","volume":"13","author":"Rubi\u00f1an","year":"2024","journal-title":"Antibiot Basel Switz"},{"key":"10.1016\/j.cmi.2025.08.018_bib45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10096-024-04994-6","article-title":"In-vitro activity of the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022","volume":"44","author":"Le Terrier","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib46","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s10096-025-05061-4","article-title":"Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: The potential of cefiderocol and ceftazidime\/avibactam plus aztreonam therapy","volume":"44","author":"Montero","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01474-23","article-title":"Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-\u03b2-lactamase (blaVIM): Infection management and molecular analysis","volume":"68","author":"Vega","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib48","first-page":"874","article-title":"Cefiderocol for the treatment of infections by VIM-type-producing gram-negative bacteria","volume":"13","author":"Kirkegaard-Biosca","year":"2024","journal-title":"Antibiot Basel Switz"},{"key":"10.1016\/j.cmi.2025.08.018_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jgar.2023.06.003","article-title":"Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway","volume":"34","author":"Brakert","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.08.018_bib50","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.cmi.2024.11.006","article-title":"Aztreonam and avibactam combination therapy for metallo-\u03b2-lactamase-producing gram-negative bacteria: A Narrative Review","volume":"31","author":"Sangiorgio","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.08.018_bib51","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s15010-024-02425-4","article-title":"In vitro activity of ceftazidime-avibactam\/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains","volume":"53","author":"Klein","year":"2025","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2025.08.018_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00751-22","article-title":"Ceftazidime-avibactam plus aztreonam for the treatment of infections by VIM-type-producing gram-negative bacteria","volume":"66","author":"Sempere","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib53","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-009-8342-x","article-title":"Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections","volume":"37","author":"Montero","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2025.08.018_bib54","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2334-13-380","article-title":"Trough colistin plasma level is an independent risk factor for nephrotoxicity: A prospective observational cohort study","volume":"13","author":"Sorl\u00ed","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib55","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/cc2358","article-title":"Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients","volume":"7","author":"Markou","year":"2003","journal-title":"Crit Care Lond Engl"},{"key":"10.1016\/j.cmi.2025.08.018_bib56","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1086\/379611","article-title":"Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa","volume":"37","author":"Linden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib57","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s00134-005-2691-4","article-title":"Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: A prospective cohort study","volume":"31","author":"Reina","year":"2005","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2025.08.018_bib58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1469-0691.2004.01043.x","article-title":"Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: The renaissance of an old antibiotic","volume":"11","author":"Michalopoulos","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.08.018_bib59","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/cid\/ciw684","article-title":"The effectiveness and safety of high-dose colistin: Prospective cohort study","volume":"63","author":"Benattar","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib60","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1128\/AAC.01015-06","article-title":"Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients","volume":"51","author":"Hachem","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib61","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","article-title":"Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate","volume":"48","author":"Horcajada","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.08.018_bib62","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/FTD.0000000000001216","article-title":"New predictive equation for the estimation of plasma concentrations of formed colistin in patients treated with colistimethate sodium for multidrug-resistant gram-negative bacterial infections","volume":"46","author":"Luque","year":"2024","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cmi.2025.08.018_bib63","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/jac\/dkz356","article-title":"Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia","volume":"74","author":"Ben\u00edtez-Cano","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib64","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13613-016-0127-7","article-title":"Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: A prospective, randomised trial","volume":"6","author":"Abdellatif","year":"2016","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.cmi.2025.08.018_bib66","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: An open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib67","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.cmi.2025.08.018_bib68","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40121-021-00570-z","article-title":"Aminoglycoside or polymyxin monotherapy for treating complicated urinary tract infections caused by extensively drug-resistant Pseudomonas aeruginosa: A propensity score-adjusted and matched cohort study","volume":"11","author":"L\u00f3pez Montesinos","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2025.08.018_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107021","article-title":"Clinical efficacy of ceftazidime\/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa","volume":"63","author":"Xu","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.08.018_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107134","article-title":"Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant gram-negative organisms: A real-life experience","volume":"63","author":"Meschiari","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.08.018_bib71","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1093\/jac\/dkae296","article-title":"Impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: A multicentre retrospective cohort study","volume":"79","author":"Vena","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib72","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-avibactam in combination with fosfomycin: A novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa","volume":"220","author":"Papp-Wallace","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.018_bib73","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib74","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkaa095","article-title":"In vitro synergy of ceftolozane\/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa","volume":"75","author":"Cuba","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib75","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jac\/dkx483","article-title":"Antibacterial activity of ceftolozane\/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa","volume":"73","author":"Monogue","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.08.018_bib76","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/cid\/ciad758","article-title":"The real crisis in antimicrobial resistance: Failure to anticipate and respond","volume":"78","author":"Bonomo","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:27:38Z","timestamp":1793503658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25004161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1198743X25004161"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.08.018","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How do I manage difficult-to-treat Pseudomonas aeruginosa infections? Key questions for today\u2019s clinicians","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}